190 related articles for article (PubMed ID: 2151045)
1. Considerations in treating hypertension: focus on risk factors.
Messerli FH
J Hum Hypertens; 1990 Dec; 4 Suppl 5():3-6. PubMed ID: 2151045
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
3. Hypertension: left ventricular hypertrophy, ventricular ectopy, and sudden death.
Ketelhut R; Messerli FH
Prim Care; 1991 Sep; 18(3):577-92. PubMed ID: 1835104
[TBL] [Abstract][Full Text] [Related]
4. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
5. Effects of antihypertensive therapy on hypertensive heart disease.
Messerli FH; Kaesser UR; Losem CJ
Circulation; 1989 Dec; 80(6 Suppl):IV145-50. PubMed ID: 2532079
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular hypertrophy, arterial hypertension and sudden death.
Messerli FH
J Hypertens Suppl; 1990 Dec; 8(7):S181-6. PubMed ID: 2151334
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
8. Prevention and reduction of left ventricular hypertrophy in the elderly.
Lavie CJ; Milani RV; Messerli FH
Clin Geriatr Med; 1996 Feb; 12(1):57-68. PubMed ID: 8653663
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular hypertrophy: an independent risk factor.
Messerli FH; Ketelhut R
J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S59-66; discussion S66-7. PubMed ID: 1726010
[TBL] [Abstract][Full Text] [Related]
10. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
Dahlöf B
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
[TBL] [Abstract][Full Text] [Related]
11. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death.
Messerli FH; Soria F
Am J Med; 1992 Aug; 93(2A):21S-26S. PubMed ID: 1387763
[TBL] [Abstract][Full Text] [Related]
12. Left ventricular hypertrophy and heart failure in women.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
14. The influence of sympathetic nervous activity on regression of cardiac hypertrophy.
Strauer BE; Bayer F; Brecht HM; Motz W
J Hypertens Suppl; 1985 Dec; 3(4):S39-44. PubMed ID: 2937889
[TBL] [Abstract][Full Text] [Related]
15. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
Messerli FH; Ketelhut R
J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S7-13. PubMed ID: 7507540
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular structural changes in hypertension: possible regression during long-term antihypertensive treatment.
Novo S; Abrignani MG; Corda M; Strano A
Eur Heart J; 1991 Dec; 12 Suppl G():47-52. PubMed ID: 1839619
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I.
Donohue TJ; Dworkin LD; Ma J; Lango MN; Catanese VM
J Investig Med; 1997 Dec; 45(9):584-91. PubMed ID: 9444886
[TBL] [Abstract][Full Text] [Related]
19. Predictors of sudden cardiac death in never previously treated patients with essential hypertension: long-term follow-up.
Saadeh AM; Jones JV
J Hum Hypertens; 2001 Oct; 15(10):677-80. PubMed ID: 11607796
[TBL] [Abstract][Full Text] [Related]
20. Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy.
Frishman WH; Skolnick AE; Strom JA
Circulation; 1989 Dec; 80(6 Suppl):IV151-61. PubMed ID: 2532080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
